Effectiveness and Drug Survival of Ixekizumab and Secukinumab in Patients with Moderate to Severe Plaque Psoriasis: Real-World Data from Bucharest, Romania

References

• Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385. doi:10.1038/jid.2012.339
   PubMed Web of Science ®Google Scholar
• Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med. 1995;332(9):581–588. doi:10.1056/NEJM199503023320907
   PubMed Web of Science ®Google Scholar
• Sampogna F, Tabolli S, Abeni D; IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) investigators. Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life. Acta Derm Venereol. 2012;92(3):299–303. doi:10.2340/00015555-1273
   PubMed Web of Science ®Google Scholar
• Kimball AB, Gladman D, Gelfand JM, et al. National psoriasis foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008;58(6):1031–1042. doi:10.1016/j.jaad.2008.01.006
   PubMed Web of Science ®Google Scholar
• Lewis-Beck C, Abouzaid S, Xie L, Baser O, Kim E. Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling. Patient Prefer Adherence. 2013;7:199–205.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10. doi:10.1007/s00403-010-1080-1
   PubMed Web of Science ®Google Scholar
• Warren RB, Smith CH, Yiu ZZN, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135(11):2632–2640. doi:10.1038/jid.2015.208
   PubMed Web of Science ®Google Scholar
• Murage MJ, Anderson A, Casso D, et al. Treatment patterns, adherence, and persistence among psoriasis patients treated with biologics in a real-world setting, overall and by disease severity. J Dermatol Treat. 2019;30(2):141–149. doi:10.1080/09546634.2018.1479725
   PubMed Web of Science ®Google Scholar
• Gniadecki R, Bang B, Bryld LE, Iversen L, Lasthein S, Skov L. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015;172(1):244–252. doi:10.1111/bjd.13343
   PubMed Web of Science ®Google Scholar
• No DJ, Inkeles MS, Amin M, Wu JJ. Drug survival of biologic treatments in psoriasis: a systematic review. J Dermatol Treat. 2018;29(5):460–466. doi:10.1080/09546634.2017.1398393
   PubMed Web of Science ®Google Scholar
• Belinchón I, Rivera R, Blanch C, Comellas M, Lizán L. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adherence. 2016;10:2357–2367. doi:10.2147/PPA.S117006
   PubMed Web of Science ®Google Scholar
• Yiu ZZN, Mason KJ, Hampton PJ, et al. Drug survival of Adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2020;183(2):294–302. doi:10.1111/bjd.18981
   PubMed Web of Science ®Google Scholar
• Lin PT, Wang SH, Chi CC. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. Sci Rep. 2018;8(1):16068. doi:10.1038/s41598-018-34293-y
   PubMedGoogle Scholar
• Egeberg A, Bryld LE, Skov L. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019;81(1):173–178. doi:10.1016/j.jaad.2019.03.048
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Shi N, Burge R, et al. Comparison of real-world treatment patterns among psoriasis patients treated with ixekizumab or Adalimumab. Patient Prefer Adherence. 2020;14:517–527. doi:10.2147/PPA.S233993
   PubMed Web of Science ®Google Scholar
• Roche H, Bouiller K, Puzenat E, et al. Efficacy and survival of biologic agents in psoriasis: a practical real-life 12-year experience in a French dermatology department. J Dermatol Treat. 2019;30(6):540–544. doi:10.1080/09546634.2018.1480746
   PubMed Web of Science ®Google Scholar
• Gordon KB, Colombel JF, Hardin DS. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(21):2102. doi:10.1056/NEJMoa1512711
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with Adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the Phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338. doi:10.1056/NEJMoa1314258
   PubMed Web of Science ®Google Scholar
• Preuss CV, Quick JI. Ixekizumab. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [ cited May 8, 2024]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK431088/. Accessed June 19, 2024.
   Google Scholar
• Aboobacker S, Kurn H, Al Aboud AM. Secukinumab. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [ cited May 8, 2024]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK537091/. Accessed June 19, 2024.
   Google Scholar
• Rosen K, Prasad V, Chen EY. Censored patients in Kaplan-Meier plots of cancer drugs: an empirical analysis of data sharing. Eur J Cancer. 2020;141:152–161. doi:10.1016/j.ejca.2020.09.031
   PubMed Web of Science ®Google Scholar
• Austin PC, Allignol A, Fine JP. The number of primary events per variable affects estimation of the subdistribution hazard competing risks model. J Clin Epidemiol. 2017;83:75–84. doi:10.1016/j.jclinepi.2016.11.017
   PubMed Web of Science ®Google Scholar
• Bland JM, Altman DG. The logrank test. BMJ. 2004;328(7447):1073. doi:10.1136/bmj.328.7447.1073
   PubMed Web of Science ®Google Scholar
• SPSS Statistics 19.0 Fix Pack 1 [Internet]; 2021 [ cited May 12, 2024]. Available from: https://www.ibm.com/support/pages/spss-statistics-190-fix-pack-1. Accessed June 19, 2024.
   Google Scholar
• Schoonjans F. MedCalc statistical software - free trial available [Internet]. MedCalc; [ cited May 12, 2024]. Available from: https://www.medcalc.org/. Accessed June 19, 2024.
   Google Scholar
• Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–409. doi:10.1016/j.jaad.2015.05.013
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484–493. doi:10.1111/bjd.13348
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831–839. doi:10.1016/S0140-6736(19)31773-8
   PubMed Web of Science ®Google Scholar
• Lee EB, Amin M, Egeberg A, Wu JJ. Drug survival of secukinumab for psoriasis in a real-world setting. J Dermatol Treat. 2019;30(2):150–151. doi:10.1080/09546634.2018.1473838
   PubMed Web of Science ®Google Scholar
• Georgakopoulos JR, Ighani A, Phung M, Yeung J. Drug survival of secukinumab in real-world plaque psoriasis patients: a 52-week, multicenter, retrospective study. J Am Acad Dermatol. 2018;78(5):1019–1020. doi:10.1016/j.jaad.2017.11.036
   PubMed Web of Science ®Google Scholar
• Brownstone ND, Hong J, Mosca M, et al. Biologic treatments of psoriasis: an update for the clinician. Biologics. 2021;15:39–51.
   PubMed Web of Science ®Google Scholar
• Jabbar-Lopez ZK, Yiu ZZN, Ward V, et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. J Invest Dermatol. 2017;137(8):1646–1654. doi:10.1016/j.jid.2017.04.009
   PubMed Web of Science ®Google Scholar